All In Biotech

Drug Trial Radar · NCT06745271

A Study to Determine How Tebapivat is Absorbed, Broken Down, and Removed From the Body and the Extent to Which Tebapivat is Made Available in the Body in Healthy Participants

A Phase I, Open-label Study to Evaluate the Absorption, Metabolism, and Excretion and to Assess the Absolute Bioavailability Following a Single Oral Dose of [14C]-Tebapivat and Concomitant Single Intravenous Microdose of [13C2,15N3]-Tebapivat to Healthy Male Participants

Last checked: Nov 19, 2026Latest source record: Mar 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

8

Actual

Start

Dec 20, 2024

Primary completion

Feb 21, 2025

Study completion Feb 21, 2025

Sponsor

Lead sponsor
Agios Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Dec 20, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The primary purpose of this study is to determine the routes, rates of elimination, mass balance of total radioactivity and metabolite profiles following a single oral dose of \[14C\]-tebapivat. To characterize the PK of tebapivat and \[13C2,15N3\]-tebapivat and determine the absolute bioavailability following single oral dose of \[14C\]-tebapivat relative to single intravenous microdose of \[13C2,15N3\]-tebapivat to healthy male participants.

Conditions

  • Healthy Participants

Interventions

  • [14C]-tebapivatDrug

    Oral Capsule

  • [13C2,15N3]-tebapivatDrug

    Intravenous Solution

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Radioactive Dose Excreted in Urine Over a Time Interval (feut1-t2) of [14C]-TebapivatTime frame: Up to Day 42
  2. Percentage of Radioactive Dose Excreted in Feces Over a Time Interval (fef t1-t2) of [14C]-TebapivatTime frame: Up to Day 42
  3. Cumulative Percentage of Radioactive Dose Excreted in Urine Over a Time Interval (Cum feut1-t2) of [14C]-TebapivatTime frame: Up to Day 42
  4. Cumulative Percentage of Radioactive Dose Excreted in Feces Over a Time Interval (Cum fef t1-t2) of [14C]-TebapivatTime frame: Up to Day 42
  5. Percentage of Total Radioactivity in Total Excreta (Feces + Urine) (Cum fe) of [14C]-TebapivatTime frame: Up to Day 42
  6. Amount of Drug Excreted in Urine (Aeu) of [14C]-TebapivatTime frame: Up to Day 42
  7. Cumulative Amount of Drug Excreted in Urine (Cum Aeu) of [14C]-TebapivatTime frame: Up to Day 42
  8. Renal Clearance (CLR) of [14C]-TebapivatTime frame: Up to Day 42
  9. Area Under the Concentration-Time Curve (AUC) From Time 0 to 168 Hours Postdose (AUC0-168) in Plasma for [14C]-Tebapivat and [13C2,15N3]-TebapivatTime frame: Up to Day 7
  10. AUC0-168 in Plasma and Whole Blood for Total RadioactivityTime frame: Up to Day 7
  11. AUC From Time 0 to the Time of the Last Quantifiable Concentration (AUC0-t) in Plasma for [14C]-Tebapivat and [13C2,15N3]-TebapivatTime frame: Up to Day 21
  12. AUC0-t in Plasma and Whole Blood for Total RadioactivityTime frame: Up to Day 42
  13. AUC Extrapolated to Infinity (AUC0-inf) in Plasma for [14C]-Tebapivat and [13C2,15N3]-TebapivatTime frame: Up to Day 21
  14. (AUC0-inf) in Plasma and Whole Blood for Total RadioactivityTime frame: Up to Day 42
  15. Maximum Observed Plasma Concentration (Cmax) for [14C]-Tebapivat and [13C2,15N3]-TebapivatTime frame: Up to Day 21
  16. Cmax in Plasma and Whole Blood for Total RadioactivityTime frame: Up to Day 42
  17. Time to Reach Cmax (Tmax) for [14C]-Tebapivat and [13C2,15N3]-TebapivatTime frame: Up to Day 21
  18. Tmax in Plasma and Whole Blood for Total RadioactivityTime frame: Up to Day 42
  19. Terminal Elimination Half-Life (t1/2) in Plasma for [14C]-Tebapivat and [13C2,15N3]-TebapivatTime frame: Up to Day 21
  20. T1/2 in Plasma and Whole Blood for Total RadioactivityTime frame: Up to Day 42
  21. Ratio of AUC0-inf for Tebapivat to AUC0-inf for Total Radioactivity in PlasmaTime frame: Up to Day 42
  22. Ratio of AUC0-inf for Total Radioactivity in Whole Blood to AUC0-inf for Total Radioactivity in PlasmaTime frame: Up to Day 42
  23. Total Clearance Following IV Administration (CL) of [13C2,15N3]-TebapivatTime frame: Up to Day 21
  24. Apparent Volume of Distribution During the Terminal Phase Following IV Administration (Vz) of [13C2,15N3]-TebapivatTime frame: Up to Day 21
  25. Apparent Volume of Distribution at Steady State Following IV Administration (Vss) of [13C2,15N3]-TebapivatTime frame: Up to Day 21
  26. Ratio of Dose-Normalized AUC0-inf of Oral Administration of [14C]-Tebapivat Relative to IV Administration of [13C2,15N3]-TebapivatTime frame: Up to Day 21
  27. Quantitation of Major Metabolites of [14C]-Tebapivat in Plasma After Oral AdministrationTime frame: Up to Day 21
  28. Quantitation of Major Metabolites of [14C]-Tebapivat in Excreta After Oral AdministrationTime frame: Up to Day 42
  29. Identification of Chemical Structure of Major Metabolites of [14C]-Tebapivat in Plasma After Oral AdministrationTime frame: Up to Day 21
  30. Identification of Chemical Structure of Major Metabolites of [14C]-Tebapivat in Excreta After Oral AdministrationTime frame: Up to Day 42

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Taha El-Shahat

    Madison, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.